Cardiff Oncology (CRDF) Fundamentals 2026 — Revenue Analysis | SniperIQ
Cardiff Oncology (CRDF) is a US-listed Healthcare company in Biotechnology with a market capitalization of $60M, trading at $0.87 on the NASDAQ. This SniperIQ fundamentals page covers Cardiff Oncology's valuation, profitability (net margin -8526.1%), revenue ($593,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cardiff Oncology's market cap?
Cardiff Oncology (CRDF) has a market capitalization of approximately $60M, trading at $0.87 on the NASDAQ. Market cap moves with the live share price.
What is Cardiff Oncology's P/E ratio?
Cardiff Oncology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Cardiff Oncology?
Cardiff Oncology runs a net profit margin of -8526.1%, a gross margin of -2105.7%, and an operating margin of -9033.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cardiff Oncology generate?
Cardiff Oncology reported revenue of $593,000 for fiscal year 2025, with net income of -$46M and earnings per share (EPS) of -0.69. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Cardiff Oncology pay a dividend?
Cardiff Oncology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Cardiff Oncology financially healthy?
Cardiff Oncology carries a debt-to-equity ratio of 0.02x and a current ratio of 3.27x, with a market beta of 1.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cardiff Oncology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cardiff Oncology (CRDF) the key facts are: market cap $60M, revenue $593,000, 52-week range 0.82-4.52. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Cardiff Oncology's full fundamentals live
Get Cardiff Oncology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.